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Abstract
Precision medicine proposes to individualize the practice of medicine based on patients’
genetic backgrounds, their biomarker characteristics and other omics datasets. After outlining
the key challenges in precision medicine, namely patient stratification, biomarker discovery
and drug repurposing, we survey recent developments in high-throughput technologies and
big biological datasets that shape the future of precision medicine. Furthermore, we provide
an overview of recent data-integrative approaches that have been successfully used in
precision medicine for mining medical knowledge from big-biological data, and we highlight
modelling and computing issues that such integrative approaches will face due to the ever-
growing nature of big-biological data. Finally, we raise attention to the challenges in
translational medicine when moving from research findings to approved medical practices.
Research highlights
 Precision medicine aims to tailor therapies to individual patient’s diseases
 High-throughput, or omics, technologies, can identify individual disease-related patterns
 Data analysis is key to translate big data to meaningful biological outputs
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Introduction
Precision medicine is based on mining vast amounts of data. The data are generated from
high-throughput screening biotechnologies studying all aspects of complex biomedical
systems to uncover new knowledge. Even though the discipline integrates diverse research
areas, including medicine, biology, biochemistry, computer science, mathematics, physics and
engineering, the extraction of meaningful data is still a major hurdle due to the complexity of
the underlying problems we are trying to address, coupled with large sizes, heterogeneity and
different time and space scales of the data. Hence, the future of precision medicine still faces
a formidable challenge on how to translate large-scale data into new knowledge to be applied
individually to each one of us to improve our health.
With substantial cost reductions in gene sequencing, single nucleotide polymorphism
(SNP) profiling, and mass spectrometry-based proteomics, omics technologies can now be
used to gain information about an individual. Efforts including integrated personal omics
(iPOP) [1] combine multi-omics data, including genomic, transcriptomic, proteomic,
metagenomic and metabolomic data, from thousands of volunteers collected over years with
the goal to assess an individual health status, illnesses and guide treatment.
Oncology is the most challenging field in precision medicine, due to the large
heterogeneity of cancers [2,3]. Until recently, medical treatments have been mainly aimed to
work for the majority of patients. However, patients suffering from the same type of cancer
can have very different mutations driving progression of their diseases. Consortiums
including The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium
(ICGC) have profiled large numbers of cancer patients with respect to the genomic variation,
DNA methylation landscapes (epigenomics), gene expression (transcriptomics), and protein
expression status (proteomics) by next-generation sequencing, protein arrays, mass
spectrometry, and other high-throughput technologies [4]. Other initiatives, such as the
Precision Medicine Initiative, aim to “deliver the right treatment at the right time, every time,
to the right person” [5]. Precision or personalized medicine can thus be seen as the next major
challenge to translate big data to the needs of individual patients and gain new information
about treatment, disease progression and ultimately develop a cure.
To do that, precision medicine (also known as “P4:” personalized, predictive, preventive
and participatory medicine) currently utilizes advanced machine learning methods to mine
large-scale omics data [6,7] and achieve three main objectives. The first one is to better sub-
type, or stratify patients. Identifying these sub-populations can be used to guide treatment
procedures of an individual and to more correctly predict treatment outcomes. The second is
to discover new bio-markers, i.e., diagnostic indicators that can be used to identify patient
sub-types. The third objective is drug repurposing aiming to identify new uses for existing
pharmacotherapies and hence shorten the time and resources needed to bring new drugs on
the market.
New avalanche of big biological data
The era of omics-technologies has seen many advances, enabling access to DNA data
(genomics), mRNA expression data (expression and coexpression data), protein data (protein-
protein interactions, protein changes), metabolites (metabolomics), to name a few. With the
advances in omics biotechnologies, steeply increasing amounts of data are being obtained.
These big data are characterized by an increase in volume (size of the data), velocity (growth
of the data) and variability (heterogeneity of the data: different types of molecular
information, captured by different technologies under different conditions), which pose
further challenges for their storing, sharing and analyses. Also, an increasing variability of the
data, i.e., access to many different types of patient data with varying degrees of noise and
completeness, additionally challenge data integration approaches. Here, we describe recent
advances in omics technologies and data analytics that are making way towards precision
medicine (Figure 1).
Functional Genomics
Two breakthrough discoveries shaped the field of functional genomics. The completion
of the human genome project catalogued most coding and non-coding sequences in the human
genome and genome editing technologies, such as CRISPR/Cas9, allowed for the targeted
disruption of a gene locus. To translate functional genomics into precision medicine, disease-
causing mutations altering gene functions need to be deciphered, as opposed to the function
on the whole gene level. Hence, precision functional genomics aims to map the phenotypic
influence of gene mutations at scale. Recent global genetic interaction maps [8] performed in
yeast generated a map using 23 million double mutants, highlighting essential genes and
functionally connected genes, which gave insight into how a certain gene works in its
environment. Since their development, CRISPR-targeted gene-knockouts have been used to
identify genome-wide genetic interaction patterns in various mammalian cell lines [9-11]. A
recent CRISPR-approach performed in mammalian cells established a functional map of
chromatin regulation, which was achieved by knocking out 107 chromatin regulators, either
individually, or paired [12]. Another study used CRISPR-based genome-wide screens to
profile gene-essentiality in 14 human acute myeloid leukemia cell lines, uncovering novel
synthetic lethal pathways for Ras [11]. Coupling CRISPR with single-cell RNA sequencing
recently led to the dissection of the unfolded protein response [13]. CRISPR has also been
used to identify HIV host dependency factors [14], highlighting the plethora of applications of
these technologies.
Epigenomics and Transcriptomics
Sequencing the human genome was the entry into studying diseases linked to genetic
variations. Yet, genes can be switched on and off depending on DNA, or histone
modifications. Epigenomics captures these modifications by applying methods, such as
bisulfite sequencing or Chip-Seq, to understand how epigenetic modifications including DNA
methylation, histone modification and chromatin accessibility affect gene expression and
regulation. Recent work uncovered DNA methylation maps of hematopoetic stem cells,
providing a novel insight into the study of blood-linked diseases [15]. The largest
epigenomics study so far comprises the analysis of 111 reference human epigenomes, which
were profiled for histone modification patterns, DNA accessibility and methylation and RNA
expression, highlighting the role of epigenomic information link gene regulation and human
disease [16]. Transcriptomics captures the dynamic state of a cell, measuring the amount of
coding and non-coding RNA over time. Expression of coding RNAs, using technologies such
as (single-cell) RNA-Seq, microarrays, or recent techniques such as NanoString, can identify
drug targets, disease biomarkers, and more recently, if an individual is a good or poor
responder to drugs [17]. Recent advances also combine CRISPR-based perturbations with
single-cell RNA sequencing to gain better molecular insights [18,19].
Proteomics and Interactomics
Diseased cells and tissues have distinct protein patterns: their protein quantities and
activities are affected. Hence, quantifying proteins and their modifications can assess health
and determine disease states. A number of high-throughput methods are used to analyze the
proteomic profiles of cancer, including mass spectrometry (MS), protein arrays or two-hybrid
based protein-protein interaction (PPI) approaches. One of the most comprehensive human
protein maps to date is “huMAP”, which comprises over 9000 published MS-experiments and
identified thousands of PPIs not previously described, allowing novel insight into protein
complexes and their connection with diseases [20]. As cancerous proteins often interact with
other proteins that trigger aberrant signaling, targeted disruption of those cancer PPIs can
offer novel therapeutic advances. In a recent study, a cancer-focussed PPI network, termed
OncoPPi, was established using high-throughput FRET technology [21]. More than 260
high-confidence PPIs were identified that have not been described in previous large-scale
datasets, allowing for gaining insight into new regulatory mechanisms of cancer genes.
Metabolomics
Metabolomics studies the collection of metabolites in a system (e.g. cell, tissue, or
organism) under certain conditions. Diseased cells and organisms have different metabolites
than their healthy counterparts. For instance, most cancer cells generate energy by glycolysis,
instead of using oxidative phosphorylation that healthy cells use [22]. With the advancement
in high-throughput profiling tools for metabolites, metabolomics studies are expected to bring
further insights into cancer biology and biomarker discovery [23]. To date, there exist more
than 190 clinically approved metabolite markers, which exceeds the biomarkers used for all
other omics technologies combined [24]. A new field of pharmacometabolomics
complements genomics with metabolomics data, allowing to assess drug responses, such as
an individual’s ability to metabolize or utilize a certain drug, which can then be related to
certain genomic aberrations [25]. Developments in metabolite imaging can potentially
improve current cancer treatments; magnetic resonance spectroscopy (MRS) and positron
emission tomography (PET) scanning have been successfully used to grade the severity of a
tumor and metabolically phenotype a variety of cancers [26].
Phenomics, Exposomics and Metagenomics
Phenomics measures phenotypic characteristics that change depending on genetic
variations and environmental factors [27]. Genome-wide association studies (GWAS) aim to
unravel the contribution of genetic variation to phenotypic diversity and have given insight
into diseases, such as diabetes and autoimmune diseases. Exposomics studies environmental
factors, such as exposure to medication, or toxic substances [28]. Physiological changes
(brain waves, heart rates etc.) and environmental exposures (radiation, toxicity) are tracked
over time and can be related to each other. Another field of omics is metagenomics, which
studies microbiomes from environmental samples. Given that there are more than 1000
microbial species living in the human intestine, the gut microbiome plays an important role in
protecting the host against pathogenic microbes and modulating immunity. The gut bacterial
flora has been shown to be linked with drug susceptibility, thus tracking bacterial flora
through mainly 16S rRNA sequencing can help identify weak spots for drug treatments.
Metagenomics plays a role in understanding the human gut microbiome, including the
diversity of the gut microbiome and its relationship to health and disease [29,30].
Radiomics
Radiomics captures large sets of quantitative data from medical images, which are then
used to predict prognosis for certain diseases that can be tomographically imaged, such as
computer tomography (CT), positron emission tomography (PET) and magnetic resonance
imaging (MRI) [31]. It is the most advanced in the field of oncology and can identify
associations between the image features and molecular markers, biological pathways and
clinical outcomes in a non-invasive way. Recently, a collaboration analyzed CT image
features from >350 patients with non-small cell lung cancer, which allowed to determine the
stage of the tumor as well as the overall patient survival [32].
Data integration and analytics
Omics data captured by different biotechnologies are usually modeled by different
types of networks (e.g. PPI networks, co-expression networks and gene regulation networks).
These biological networks were originally studied in isolation from each other, which led to
better understanding of gene functions [33] and molecular organization of the cell [34], as
well as to improving therapeutics [35-39]. For these omics network types, substantial insights
were gained by utilizing topological descriptors, such as graphlets (small induced subgraphs
representing the local wiring patterns around nodes in a network) [40], which revealed that
molecules involved in similar functions tend to group together in a network and are similarly
wired [41]. However, a complex disease such as cancer can be caused by a combination of
genetic, molecular, environmental and lifestyle factors, which are only partially captured by
each individual data type. By coupling network analytics with data integration, precision
medicine untangle this complexity, highlighting common molecular mechanisms between
seemingly unrelated diseases that emerge from the complementarity of the network data
[35,37,39,42].
While many machine learning techniques have been proposed to integrate and mine
biological data, matrix factorization (a co-clustering and dimensionality reduction approach)
recently gained significant interest for performing patient stratification, or for uncovering
disease genes [42]. It has several advantages over other machine learning techniques. First, it
is computationally more efficient than Bayesian approaches. Also, it avoids potential
information loss occurring in kernel-based approaches that are due to transforming of the data
into the same feature space. Finally, unlike deep neural networks, it does not require large
training datasets.
One of the first of the matrix factorization based approaches is iCluster [43], which
integrates DNA copy number variation and gene expression data to stratify cancer patients.
Each data type in iCluster is represented as a matrix of measurements for the set of patients
(e.g., mRNA expression values) and all matrices, A, representing different types of data, are
simultaneously factorized into a product of two low-dimensional matrices: A ≈ WH. The
dimensionality of the low-dimensional matrices W and H represents the number of cancer
subtypes and hence, it is a predefined parameter. The first matrix, W, also called the
coefficient matrix, is specific to each data type, while the second matrix, H, also called the
cluster indicator matrix, is shared across the decomposition and is used to associate each
patient to a cancer subtype according to all data. For breast and lung cancers, iCluster
identified novel subgroups with statistically different clinical outcomes as a result of
combined information from both data types. This approach was extended to better account for
joint variations across data types, as well as variations specific to each data type [44]. The
extension, JIVE, performed a better characterization of tumor subtypes, as well as a better
understanding of the biological interactions between different data types. Another matrix
factorization based approach is Network-Based Stratification (NBS) [45], which integrates
somatic mutation profiles with molecular networks that contain biological pathways. NBS
was applied on ovarian, uterine, and lung cancer patients from TCGA database, and it yielded
cancer subtypes with different clinical outcomes, response to therapies, and tumor histologies.
While the above presented methods focus mainly in stratifying patients, Gligorijevic
et al. [36] recently proposed a patient centric data-fusion framework based on matrix tri-
factorization (in which each data matrix is decomposed into the product of three matrix
factors) that answer all P4 challenges simultaneously by collectively mining patients’ somatic
mutation profiles, molecular interaction networks, drug-target interactions and drug chemical
similarities. When applied on ovarian cancer patients from TCGA, this framework
successfully stratified ovarian cancer patients into subgroups with statistically significantly
different clinical outcomes, identified new oncogenes and predicted new drug candidates that
could be repurposed to treat ovarian cancer patients.
Despite methodological advances, there are key modelling and mining challenges
blocking the way forward in precision medicine. Omics data are widely modeled as binary
networks that model only pairwise relationships between the data points and cannot capture
multi-scale organization of the data, or their dynamics. Thus, new models are needed to fully
capture the complexity of biomedical datasets. These models may be based on generalization
of network (also called graph) representations into hyper-network- and multi-layer network
models, or on other mathematical formalisms for which descriptors need yet to be developed.
In this respect, hypergraphlets, the generalization of graphlets to hypergraphs, have recently
been introduced [46], but have not been applied for mining biological networks yet. Once
applied, they have a potential to uncover new biomedical knowledge currently hidden in the
complexity of multi-scale molecular organization.
Data-integration will also face computational issues stemming from the above
described multi-scale nature, large sizes, heterogeneity, complexity, dynamics and
stochasticity of the biomedical data, coupled with computational intractability of the problems
that we are trying to address from the data [47]. The next-generation data integration
algorithms will have to account for all of these complexities. Some ways forward may include
tensor factorization, which can be viewed as a generalization of matrix factorization for multi-
layer networks, but which suffers from large memory requirements and low scalability that
prevent its usage for integrating large scale biomedical data. This could be addressed by
developing massively parallel algorithms that will be executed on large computing
infrastructures, or in a cloud.
Steps towards translational medicine
As illustrated above, high-throughput omics technologies can complement clinical
evaluations by identifying previously unknown subtypes of disease pathologies, allowing for
better prognoses and responses to treatments. There are efforts to directly apply omics
technologies in precision medicine. For instance, Editas Medicine, a Cambridge-
(Massachusetts) based company, aims to use CRISPR/Cas9 to correct disease-causing
mutations directly in humans. The Jackson Laboratory Center for Precision Genetics (JCPG)
aims to use CRISPR-engineered animal models of incurable and genetically complex human
diseases to offer personalized medicine. Researchers have already edited human embryos to
try to correct mutations in the hemoglobin gene that underlie the fatal blood disorder beta
thalassemia [48]. Overall, 86 embryos were treated, but only 28 were successfully edited. In
addition to the low efficiency, many unintended mutations were also created in the genomes
of treated embryos. Recently, a team at Oregon Health and Science University edited human
embryos targeting a mutation causing hypertrophic cardiomyopathy, apparently minimizing
off-target and mosaic effects [49]. CRISPR/Cas9 has recently been used to target two
clinically relevant genes in human hematopoietic stem cells that are important for HIV
infection [50].
Another strategy, called immunotherapy, has recently been employed using CRISPR-
genome editing in T cells [51]. After its FDA approval, Novartis recently started
commercializing a Leukemia therapy called Kymriah. Patients’ T-cells are genetically
modified to include a new gene (CAR, a chimeric antigen receptor) that directs the edited T-
cells to target and kill leukemia cells that express a specific antigen (CD19) on their surface.
This treatment notably raised a polemic due to its prohibitive cost (~ 475K USD).
With a growing availability of electronical health records (EHR), individualized
treatments of patients are becoming increasingly realistic. EHRs include personal and family
medical history, lab tests and demographic data. As presented in 2015 by U.S. Precision
Medicine Initiative, incorporating omics data and knowledge into electronic health records is
as a necessary step for delivering precision medicine. Recently, portable biosensors have been
used to measure individual physiological changes over time. 43 individuals were assessed and
250,000 measurements recorded daily. The data showed a correlation between individuals and
their lifestyle, stress levels and early signs of inflammatory response [52].
The ambitious aim of extracting meaningful information from big omics data to benefit
an individual’s health outcomes faces many challenges associated not only with data analysis,
but also with more downstream aspects. For instance, how to effectively translate information
from omics data into medical knowledge that is to be used in GP practice? Additional hurdles
include major ethical issues. Finally, clinical trials and FDA approvals will pose challenges
that researchers, pharmaceutical companies, governments and medical healthcare takers will
collectively need to tackle.
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Figure legend
Figure 1. Underlying molecular mechanisms of an individual’s disease state (disease
phenotypes) can be revealed through collection of omics data (data generation and collection),
such as information about DNA (genomics), mRNA (expression and coexpression), proteins
(proteomics) or metabolites (metabolomics), among many others (see text for details).
Clinical data such as electronic health records or patient information can be combined and
integrated into omics data (data integration and analysis). Extraction of biological data can
help identify new disease genes and biomarkers, increase disease progression prediction and
new drug therapy development. Ultimately, extracted information could lead to personalized
medicine, tailored to the disease of an individual (precision medicine).
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